Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a herbal remedy fix kidney side effects of cancer drugs?

NCT ID NCT07358520

Symptom relief Sponsor: Fudan University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether Huaier Granules, a traditional Chinese medicine, can reduce proteinuria (excess protein in urine) caused by the cancer drugs bevacizumab or anlotinib in lung cancer patients. About 40 adults will be enrolled and followed for 16 weeks to see if the granules help control this side effect. It is a small, early-phase trial, so results will be preliminary.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Huaier Granules (a traditional Chinese medicine extract)
What this could lead to
If it works, this could offer a way to manage proteinuria side effects from certain lung cancer treatments, helping patients stay on their cancer therapy.
What could go wrong
This is a very small, early-phase trial with only 40 participants. It tests a traditional remedy, and results may not be conclusive or widely applicable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years; * Histopathologically confirmed diagnosis of lung cancer; * Receiving Bevacizumab or Anlotinib treatment; * Positive urine protein detection, with 0.15g \< 24-hour urinary protein quantification \< 3.5g; * No treatment with Huaier Granules within one month prior to enrollment; * Expected survival time not less than 6 months; * Voluntary participation in this study and provision of signed informed consent. Exclusion Criteria: * Known allergy, contraindication, or caution to any component of Huaier Granules; * Inability to take oral medication; * Required or ongoing use of drugs known to potentially affect proteinuria, including but not limited to ACE inhibitors, glucocorticoids (\>3 weeks), and Chinese patent medicines (as per respective drug prescribing information); * Proteinuria caused by underlying diseases, including but not limited to nephropathy, hypertension, urinary tract infection, systemic lupus erythematosus, multiple myeloma, etc.; * Women who are pregnant, breastfeeding, or planning pregnancy; * Currently participating in other clinical trials investigating drugs for treating proteinuria; * Refusal to cooperate with follow-up; * Any other reasons deemed by the investigator as unsuitable for participation in this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung cancer proteinuria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Proteinuria

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China

  • Xuzhou Central Hospital

    Xuzhou, Jiangsu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.